Biogen shares rocket up as Mylan's challenge to Tecfidera patents is slapped down
Biogen $BIIB just won one of the biggest fights it’s ever faced.
The big biotech beat Mylan’s challenge on the patents that guard their cash cow, Tecfidera, the multiple sclerosis drug that drove the company’s comeback under George Scangos and sustains his successor Michel Vounatsos as they search for new drugs.
In the inter partes review ruling, the Patent Trial and Appeal Board — or PTAB — determined:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.